Roivant Sciences (NASDAQ:ROIV) Releases Earnings Results, Beats Expectations By $0.04 EPS

Roivant Sciences (NASDAQ:ROIV) released its earnings results on Monday. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04, Zacks reports. Roivant Sciences had a negative return on equity of 14.65% and a net margin of 3,827.42%.

Roivant Sciences Price Performance

ROIV opened at $10.49 on Wednesday. The business has a 50 day simple moving average of $11.48 and a two-hundred day simple moving average of $11.60. The firm has a market capitalization of $7.64 billion, a price-to-earnings ratio of 1.86 and a beta of 1.25. Roivant Sciences has a one year low of $9.76 and a one year high of $13.06.

Insiders Place Their Bets

In other Roivant Sciences news, CIO Mayukh Sukhatme sold 689,495 shares of the company’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $12.01, for a total transaction of $8,280,834.95. Following the transaction, the executive now owns 18,836,547 shares in the company, valued at approximately $226,226,929.47. This represents a 3.53 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sciences Ltd. Roivant bought 16,845,010 shares of Roivant Sciences stock in a transaction on Monday, January 13th. The shares were purchased at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the acquisition, the director now directly owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 1,942,629 shares of company stock worth $23,034,486. Company insiders own 7.90% of the company’s stock.

Wall Street Analysts Forecast Growth

ROIV has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research note on Thursday, January 30th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Roivant Sciences presently has a consensus rating of “Buy” and an average target price of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.